It was a pleasure to catch up with Dr Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about the problems with the clinical utility of vascular endothelial growth factor inhibitors and the issues around durability and ensuring good outcomes in real-world settings, as opposed to just in clinical trials.
Questions:
- How do age-related macular degeneration (AMD) outcomes in real-world settings with vascular endothelial growth factor (VEGF) inhibitors differ from those in clinical trials, and what is the reason for this? (0:23)
- What other factors limit the clinical utility of VEGF inhibitors in the treatment of AMD? (1:48)
The presentation entitled, New and Emerging Neovascular AMD Treatments was presented at the Hawaiian Eye and Retina 2023 meeting, 14–20 January, 2023.
Disclosures: Carl Regillo has served as a consultant for 4DMT, Adverum, Allergan, Annexon, Apellis, Clearside, Curacle, Eyepoint, Genentech, Graybug, Iveric, Janssen, Kodiac, Lineage, Merck, NGM, Novartis, Ocugen, Ocuterra, Ray, RegenXBio, Stealth, Thea, Zeiss, and has received grant/research support from Adverum, Allergan, Annexon, Apellis, Astellis, Curacle, Eyepoint, Genentech, Graybug, Gyroscope, Iveric, Kodiac, Lineage, NGM, Notal, Novartis, Ocugen, Ocuterra, Opthea, Regeneron, RegenXBio.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Lisa Glass.
Filmed as a highlight of Hawaiian Eye and Retina 2023.
Click here for more content from Dr Carl Regillo.
